# EGFR Mutations and Tyrosine Kinase Inhibitors: Structural Insights and Therapeutic Advances

## TL;DR

This review discusses how EGFR mutations drive lung cancer and how tyrosine kinase inhibitors work, including challenges with drug resistance and new treatment strategies.

## Contribution

The paper offers a structural analysis of EGFR mutations and evaluates new TKIs for overcoming resistance in NSCLC.

## Key findings

- EGFR mutations in the tyrosine kinase domain drive NSCLC progression and treatment resistance.
- Secondary mutations and alternative pathways contribute to resistance against tyrosine kinase inhibitors.
- New TKIs are being developed to address resistance and improve treatment outcomes.

## Abstract

Epidermal Growth Factor Receptor (EGFR) mutations are
a major driver
of nonsmall cell lung cancer (NSCLC), particularly among nonsmoking
populations. Oncogenic mutations within the tyrosine kinase (TK) domain
of EGFR play a critical role in activating downstream signaling pathways
that promote tumor growth and survival. Targeting this domain has
proven effective in developing therapeutic agents for NSCLC. However,
treatment with these inhibitors often leads to acquired resistance
due to secondary on-target mutations and activation of alternative
pathways, making disease management increasingly challenging and necessitating
continuous development of novel drugs and strategies. This review
provides a comprehensive structural analysis of EGFR, highlighting
key activating and resistance-associated mutations and their implications
for drug resistance. It also examines mutation-driven resistance mechanisms
and the current landscape of novel tyrosine kinase inhibitors (TKIs)
in clinical development.